Johnson & Johnson
Johnson & Johnson (NYSE:JNJ) is about as dependable — and boring — a stock as you’ll ever find.
Among its attention-grabbing products: Johnson’s baby powder. Bengay. Listerine. Tucks Hemorrhoidal Ointment. Pepcid heartburn treatment. Band-Aids. Visine eye care. That’s a product lineup that will put you to sleep faster than its Zyrtec allergy medicine.
Of course, all those household necessities have powered JNJ’s dividend for nearly 70 years, with steady year-by-year growth to its current 61-cent payout (good for a 3.3% yield at current prices). That certainly helps make up for admittedly slower, if not steady, returns of roughly 4% annually … though 13% gains in the past year have pushed Johnson & Johnson’s stock into new all-time highs around $74.
JNJ’s diversified line of offerings should keep that needle pointed north.